CRS Clinical Research Services Management GmbH

The Clinical Pharmacology Unit at CRS Clinical Research Services Management GmbH conducts studies that explore novel antimicrobial strategies for bacterial infections and mycoses, focusing on how organ impairment may affect drug behavior.

• Pharmacokinetic evaluation of antibiotics in renal impairment
• Safety profiling of antifungal agents in hepatic dysfunction
• Drug‑interaction assessments with standard of care therapies

By integrating healthy volunteer data with patients experiencing kidney or liver challenges, the site seeks to optimize dosing recommendations and improve therapeutic outcomes for infectious diseases.

Research at the Kiel facility emphasizes the impact of organ function on treatments for ulcerative colitis and related gastrointestinal conditions, evaluating both efficacy and tolerability.

• Effect of hepatic impairment on drug exposure
• Pharmacokinetic modeling in patients with moderate to severe ulcerative colitis
• Safety monitoring in combined liver‑kidney dysfunction scenarios

The trials aim to refine therapeutic dosing for digestive disorders while ensuring safety across a spectrum of liver function levels.

The site advances therapies for autoimmune conditions such as systemic lupus erythematosus, cutaneous lupus erythematosus, dermatomyositis, and moderate to severe atopic dermatitis, testing new molecules for effectiveness and safety.

• Efficacy assessment using disease‑specific activity scores
• Impact of renal and hepatic impairment on immune‑modulating agents
• Biomarker analysis for treatment response

These investigations help determine optimal dosing strategies for patients with complex immune dysregulation, supporting better disease control.

Studies target conditions like rheumatoid arthritis and inflammatory muscle disorders, focusing on how impaired kidney function may alter drug handling.

• Pharmacokinetic studies in participants with varying degrees of renal impairment
• Safety evaluation of novel anti‑inflammatory agents
• Correlation of drug levels with clinical improvement scores

By characterizing drug behavior in musculoskeletal disease patients, the research supports personalized dosing and enhanced therapeutic benefit.

Investigations include the influence of metabolic challenges on medication exposure, particularly in subjects with renal impairment or hepatic impairment.

• Assessment of drug clearance across mild, moderate, and severe kidney dysfunction
• Evaluation of hepatic function impact on oral and subcutaneous formulations
• Integration of metabolic biomarkers to guide dosing

The goal is to ensure that patients with metabolic comorbidities receive safe and effective treatment regimens.

The unit explores fundamental immune processes, measuring how new therapeutics modulate the immune system under conditions of organ impairment.

• Pharmacodynamic profiling of immune‑targeted compounds
• Effect of renal and hepatic dysfunction on immune response markers
• Safety surveillance for immunomodulatory adverse events

These studies provide insight into the mechanisms of action and help tailor therapies for patients with altered immune physiology.